Cargando…

Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report

BACKGROUND: Favipiravir is used in treatment of Covid-19 patients. We aimed to share of ocular surface fluorescence in a patient after Favipiravir treatment in this case report. CASE PRESENTATION: A 20-year-old male patient declared no known systemic disease prior to Covid-19. He applied to us with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doran, Mehmet Ali, Aytogan, Hasan, Ayıntap, Emre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276213/ https://www.ncbi.nlm.nih.gov/pubmed/34256791 http://dx.doi.org/10.1186/s12985-021-01610-3

Ejemplares similares

Outcomes of External Dacryocystorhinostomy under General and Local Anesthetics in a Tertiary Clinic
por: Aytogan, Hasan, et al.
Publicado: (2022)

Comparing the symmetry of upper eyelid following unilateral ptosis correction
por: Aytogan, Hasan, et al.
Publicado: (2021)

Effectiveness of favipiravir in COVID-19: a live systematic review
por: Özlüşen, Batu, et al.
Publicado: (2021)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

A case of cutaneous candidiasis of upper eyelid in association with facial paralysis
por: Aytoğan, Hasan
Publicado: (2020)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Elevation of Serum Transaminase Levels Due to Favipiravir Use in the Treatment of COVID-19
por: Bayram, Mehmet, et al.
Publicado: (2021)

Favipiravir: Hyperuricaemia: case report
Publicado: (2021)

Follow-up of Favipiravir-Induced Nail Fluorescence: Implications for Nail and Drugs
por: Güder, Hüsna, et al.
Publicado: (2023)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
por: El-Awady, Mohamed, et al.
Publicado: (2022)

Favipiravir and hyperuricemia in patients with COVID-19—suggestions for future studies
por: Kow, Chia Siang, et al.
Publicado: (2023)

Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra
por: Mortaz, Esmaeil, et al.
Publicado: (2021)

Favipiravir: Drug fever: case report
Publicado: (2021)

ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol
por: Guner, Abdullah Emre, et al.
Publicado: (2021)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
por: Karatas, Hacer, et al.
Publicado: (2022)

Favipiravir‐induced nephrotoxicity in a patient with COVID‐19: A case report
por: Abdelbary, Asmaa A., et al.
Publicado: (2021)

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
por: Pilkington, Victoria, et al.
Publicado: (2020)

Favipiravir: Various toxicities: 3 case reports
Publicado: (2022)

Favipiravir: Erythema and transaminase elevation: case report
Publicado: (2022)

Favipiravir: Lack of efficacy following off-label treatment: case report
Publicado: (2021)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
por: Dabbous, Hany M., et al.
Publicado: (2021)

Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient
por: Tawara, Junsuke, et al.
Publicado: (2021)

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
por: Manabe, Toshie, et al.
Publicado: (2021)

Favipiravir: insight into the crystal structure, Hirshfeld surface analysis and computational study
por: Babashkina, Maria G., et al.
Publicado: (2021)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Evaluation of the effect of favipiravir on patients with COVID-19
por: Kamali, Alireza, et al.
Publicado: (2023)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020)

1147. Regional Trends in Favipiravir and Steroid Use in the Treatment of COVID-19
por: Asai, Yusuke, et al.
Publicado: (2022)

Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
por: Tatar, Erhan, et al.
Publicado: (2020)

Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
por: Tawfik, Abdulrahman, et al.
Publicado: (2022)

An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19
por: Raiturcar, Tanvi P, et al.
Publicado: (2021)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7gh42e6re2n2418h67c9kugfva